Treatment News : Elevated Heart and Kidney Disease Risk Despite HIV Treatment?

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » May 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

May 18, 2010

Elevated Heart and Kidney Disease Risk Despite HIV Treatment?

People with HIV have higher levels of blood markers associated with cardiovascular and kidney disease even when their virus is suppressed by antiretroviral (ARV) treatment, according to a new study published in the June 15 issue of The Journal of Infectious Diseases.

Mounting evidence strongly suggests that HIV causes inflammation, whereby cells in the body are in a state of chronic high alert. These inflamed cells produce proteins—including high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL6), D-dimer and cystatin-C—that are associated with higher risk for developing cardiovascular and kidney disease. Researchers have documented that these inflammatory proteins are associated with disease risk in both HIV-positive and HIV-negative individuals.

What has remained unknown, however, is how much these inflammatory proteins are elevated in people with HIV, compared with HIV-negative people, and the degree to which suppression of HIV by ARVs might lower inflammation.

To distinguish levels of inflammatory proteins in HIV-positive and HIV-negative people, Jacqueline Neuhaus, MS, from the University of Minnesota, and her colleagues compared data on the proteins from three different studies: the Strategies for Management of Anti-Retroviral Therapy (SMART) study, the Multi-Ethnic Study of Atherosclerosis (MESA) study and the Coronary Artery Development in Young Adults (CARDIA) study. All of the participants in the SMART study were HIV positive, while the vast majority of those in MESA and CARDIA were believed to be HIV negative.

There were a number of important differences between participants in SMART and those in MESA and CARDIA aside from HIV status. SMART study volunteers were more likely to be male and black. They were also more likely to smoke, to take lipid and blood pressure medication, and to have higher total cholesterol to HDL (“good”) cholesterol ratios.

Neuhaus and her colleagues found that levels of all the inflammatory proteins were higher in HIV-positive people than in HIV-negative individuals. In general, levels of the proteins ranged from 18 to 118 percent higher in people with HIV, depending on the protein measured and whether the researchers compared SMART with MESA or CARDIA. The elevation in inflammatory proteins held true even when Neuhaus’s team factored in viral load, CD4 count, sex, smoking and other factors that could have influenced the results. Reductions in viral load due to ARV therapy did significantly reduce inflammatory protein levels in people with HIV. Nevertheless, inflammatory protein levels remained higher in people with HIV—even in those with undetectable virus—than in HIV-negative individuals.

Among people on ARV medication, those taking a regimen including a protease inhibitor were likely to have lower inflammatory protein levels than those taking a non-nucleoside reverse transcriptase regimen (NNRTI). As has been previously reported, people taking Ziagen (abacavir) had elevated inflammatory protein levels.

The authors state that a potential weakness of the study is the significant differences in the make-up of the participants in SMART, compared with MESA and CARDIA. Though they attempted to account for differences in sex, race, smoking status and other factors, the researchers acknowledge that these or other differences could explain some of the elevation in inflammatory markers among people with HIV.

However, Michael Dubé, MD, and Fred Sattler, MD, from the University of Southern California, point out in an accompanying editorial how carefully Neuhaus and her coauthors preceded with their study. In discussing the study’s results, Dubé and Sattler state, “Elevated levels of these markers/mediators represent an important potential explanatory variable in understanding the increased incidence of complications related to chronic inflammation among HIV-infected persons.”

Dubé and Sattler conclude: “It will be critical that future studies examine mechanisms underlying persistent immune activation/inflammation, as well as test strategies for modulating inflammation, to effectively intervene in these long-term complications that are holding our patients back from more complete recovery from HIV infection.”

Search: Cardiovascular disease, kidney disease, inflammation, inflammatory proteins, IL-6, hsCRP, cystatin-C, D-dimer, Jacqueline, Neuhaus, Michael Dube, Fred Sattler


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (2 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    acousticmat
    Tucson
    Arizona


    soy_Ric
    Rochester
    New York


    Fred9774
    Brooklyn
    New York


    clintonjrsyr
    syracuse
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.